RxDoctor Payments Data

Michael Schafer, MD

Gastroenterology · Omaha, NENPI 1538240007

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $21,405 of the $30,109 with a category attached, or 71.1%. Boston Scientific accounts for 96.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $11,206 and has fallen 90.1% since, to $1,107 in 2025. Among gastroenterology clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$30,109in general payments, 2019–2025

Across 122 payments — averaging $246.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$29K
  • Nestle Healthcare Nutrition Inc.$203
  • Johnson & Johnson$163
  • Sanofi$158
  • AbbVie$143
  • Pfizer$125
  • plus $296 from 11 others

What the payments were for

  • Speaking & faculty fees$21,40571%
  • Travel & lodging$2,5268%
  • Food & beverage$6,10520%
  • Education$430%
  • Other$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,109 in reported general payments places this provider in the 90th percentile of 89 gastroenterology providers in Nebraska.

See all gastroenterology providers in Nebraska

Medicare billing

Part B allowed, 2024
$225,690
Medicare patients
880
Services billed
1,396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$81,739
CreonLipase/Protease/Amylase37$61,234
LialdaMesalamine11$14,206
VoqueznaVonoprazan Fumarate13$8,286
Mesalamine28$5,682
Balsalazide Disodium25$4,543
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg159$3,299
Ursodiol22$2,128
Sucralfate17$1,981
Pantoprazole Sodium160$1,738
Omeprazole88$1,361
Rabeprazole Sodium27$941
Gavilyte-NSodium Chloride/Nahco3/Kcl/Peg23$300
Amitriptyline Hcl21$266
Famotidine21$251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$143$61,23437 claims
Phathom Pharmaceuticals, Inc.Voquezna$32$8,28613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 89 gastroenterology providers in Nebraska.

Other gastroenterology in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →